Rhumbline Advisers Ironwood Pharmaceuticals Inc Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 337,965 shares of IRWD stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
337,965
Previous 365,701 7.58%
Holding current value
$1.5 Million
Previous $2.38 Million 41.74%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$3.93 - $7.04 $109,002 - $195,261
-27,736 Reduced 7.58%
337,965 $1.39 Million
Q2 2024

Aug 01, 2024
BUY
$5.58 - $8.61 $14,379 - $22,187
2,577 Added 0.71%
365,701 $2.38 Million
Q1 2024

May 09, 2024
SELL
$8.32 - $15.45 $795,550 - $1.48 Million
-95,619 Reduced 20.84%
363,124 $3.16 Million
Q4 2023

Feb 08, 2024
BUY
$8.79 - $11.51 $4,456 - $5,835
507 Added 0.11%
458,743 $5.25 Million
Q3 2023

Nov 09, 2023
BUY
$8.25 - $11.35 $32,463 - $44,662
3,935 Added 0.87%
458,236 $4.41 Million
Q2 2023

Aug 08, 2023
BUY
$10.1 - $11.6 $388,607 - $446,321
38,476 Added 9.25%
454,301 $4.83 Million
Q1 2023

May 11, 2023
BUY
$10.37 - $12.56 $163,493 - $198,020
15,766 Added 3.94%
415,825 $4.37 Million
Q4 2022

Feb 14, 2023
BUY
$9.9 - $12.43 $101,168 - $127,022
10,219 Added 2.62%
400,059 $4.96 Million
Q3 2022

Nov 10, 2022
BUY
$10.14 - $12.38 $794,935 - $970,542
78,396 Added 25.17%
389,840 $4.04 Million
Q2 2022

Aug 11, 2022
BUY
$11.05 - $12.72 $1.62 Million - $1.87 Million
146,836 Added 89.2%
311,444 $3.59 Million
Q1 2022

May 12, 2022
BUY
$10.61 - $12.88 $66,598 - $80,847
6,277 Added 3.96%
164,608 $2.07 Million
Q4 2021

Feb 10, 2022
SELL
$10.86 - $13.95 $342,426 - $439,857
-31,531 Reduced 16.61%
158,331 $1.85 Million
Q3 2021

Nov 12, 2021
BUY
$11.92 - $13.92 $73,582 - $85,928
6,173 Added 3.36%
189,862 $2.48 Million
Q2 2021

Aug 05, 2021
SELL
$10.16 - $13.11 $84,307 - $108,786
-8,298 Reduced 4.32%
183,689 $2.36 Million
Q1 2021

May 06, 2021
SELL
$9.04 - $11.86 $94,178 - $123,557
-10,418 Reduced 5.15%
191,987 $2.15 Million
Q4 2020

Feb 10, 2021
SELL
$9.05 - $12.2 $129,234 - $174,216
-14,280 Reduced 6.59%
202,405 $2.31 Million
Q3 2020

Nov 12, 2020
SELL
$8.99 - $10.74 $567,134 - $677,532
-63,085 Reduced 22.55%
216,685 $1.95 Million
Q2 2020

Aug 13, 2020
BUY
$9.14 - $11.97 $371,001 - $485,874
40,591 Added 16.97%
279,770 $2.89 Million
Q1 2020

May 06, 2020
BUY
$8.58 - $14.01 $166,597 - $272,032
19,417 Added 8.84%
239,179 $2.41 Million
Q4 2019

Feb 05, 2020
BUY
$8.22 - $14.0 $42,702 - $72,730
5,195 Added 2.42%
219,762 $2.93 Million
Q3 2019

Oct 23, 2019
BUY
$8.59 - $10.96 $82,592 - $105,380
9,615 Added 4.69%
214,567 $1.84 Million
Q2 2019

Aug 14, 2019
BUY
$9.8 - $12.89 $199,547 - $262,466
20,362 Added 11.03%
204,952 $2.24 Million
Q1 2019

May 01, 2019
SELL
$8.27 - $12.73 $14,149 - $21,781
-1,711 Reduced 0.92%
184,590 $2.5 Million
Q4 2018

Jan 31, 2019
BUY
$7.8 - $16.13 $478,483 - $989,478
61,344 Added 49.09%
186,301 $1.93 Million
Q3 2018

Nov 07, 2018
SELL
$14.31 - $17.65 $127,859 - $157,702
-8,935 Reduced 6.67%
124,957 $2.31 Million
Q2 2018

Aug 06, 2018
BUY
$11.83 - $16.2 $73,760 - $101,007
6,235 Added 4.88%
133,892 $2.56 Million
Q1 2018

May 02, 2018
SELL
$11.13 - $13.63 $31,386 - $38,436
-2,820 Reduced 2.16%
127,657 $1.97 Million
Q4 2017

Feb 09, 2018
SELL
$12.16 - $14.58 $306,407 - $367,386
-25,198 Reduced 16.19%
130,477 $1.96 Million
Q3 2017

Nov 06, 2017
BUY
$12.07 - $14.87 $1.88 Million - $2.31 Million
155,675
155,675 $2.46 Million

Others Institutions Holding IRWD

# of Institutions
237
Shares Held
162M
Call Options Held
11.2M
Put Options Held
9.1K
View Full List

About IRONWOOD PHARMACEUTICALS INC

IRWD Quotes by TradingView
  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $682M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email